Early integration of high dose methotrexate to frontline DLBCL therapy does not impact CNS relapse compared to end of treatment delivery: a multicentre international analysis of 1384 patients
Authors
Wilson, M. R.Eyre, T. A.
Kirkwood, A. A.
Doo, N. W.
Soussain, C.
Choquet, S.
Martinex-Calle, N.
Preston, G.
Ahearne, M. J.
Schorb, E.
Moles-Moreau, M. P.
Ku, M.
Rusconi, C.
Khwaja, J.
Narkhede, M.
Lewis, K. L.
Calimeri, T.
Durot, E.
Renaud, L.
Ovlisen, A. K.
McIlroy, G.
Ebsworth, T.
Elliot, Johnathon
Santarsiere, A.
Ricard, L.
Shah, N.
Liu, Q.
Zayac, A.
Vassallo, F.
Lebras, L.
Roulin, L.
Lombion, N.
Manos, K.
Fernandez, R.
Hamad, N.
Lopez-Garcia, A.
O'Mahony, D.
Gounder, P.
Forgeard, N.
Lees, C.
Agbetiafa, K.
Strussmann, T.
Htut, T. W.
Clavert, A.
Scott, H. W.
Guidetti, A.
Barlow, B. R.
Smith, J.
El-Galaly, T. C.
Cheah, C. Y.
Ferreri, A. J. M.
Miall, F.
Fox, C. P.
Cwynarski, K.
McKay, P.
Affiliation
Beatson West of Scotland Cancer Centre, Glasgow, United KingdomIssue Date
2021
Metadata
Show full item recordCitation
Wilson MR, Eyre TA, Kirkwood AA, Doo NW, Soussain C, Choquet S, et al. Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treat ent Delivery: A Multicentre International Analysis of 1384 Patients. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398801226.Journal
BloodDOI
10.1182/blood-2021-144820Additional Links
https://dx.doi.org/10.1182/blood-2021-144820Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-144820